| Date | Title | Description |
| 30.04.2024 | Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion | ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent Truvaga Plus consumer study ... |
| 08.04.2024 | electroCore Announces the Launch of Truvaga Plus® for General Wellness | ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general ... |
| 02.04.2024 | electroCore Expands Intellectual Property Portfolio | electroCore Granted Two New U.S. Patents
ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue n... |
| 13.03.2024 | electroCore Announces Fourth Quarter and Full Year 2023 Financial Results | Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022
ROCKAWAY, N.J., March 13, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic med... |
| 13.03.2024 | electroCore Announces Fourth Quarter and Full Year 2023 Financial Results | - |
| 12.03.2024 | electroCore to Participate in Upcoming Investor Conferences | - |
| 05.03.2024 | electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 | - |
| 06.02.2024 | electroCore Expands Intellectual Property Portfolio | ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to ... |
| 09.01.2024 | electroCore Expands Intellectual Property Portfolio | ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to ... |
| 26.12.2023 | electroCore Expands Intellectual Property Portfolio | electroCore Granted Two New U.S. Patents |
| 17.10.2023 | electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue | Extension maintains listing through March 17, 2026 |
| 10.10.2023 | Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress | VANQUISH Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) |
| 27.09.2023 | gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD) | Two prospective, peer-reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD |
| 26.09.2023 | electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology | ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to... |
| 31.07.2023 | electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules | ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to cert... |
| 25.07.2023 | gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD) | ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervi... |
| 18.07.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS Technology | ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent rel... |
| 13.07.2023 | electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC | ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neu... |
| 11.07.2023 | electroCore Provides Select Second Quarter 2023 Financial Guidance | Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 |
| 06.07.2023 | gammaCore™ Selected for Study Funded by NFL and NFL Players Association on Alleviating Concussion Symptoms | Research grants jointly awarded to independent medical researchers studying alternative pain management treatments at American Society of Pain & Neuroscience and Emory University |
| 27.06.2023 | electroCore’s TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environme... | ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Perform... |
| 26.05.2023 | electroCore, Inc. Announces Departure of JP Errico from the Board of Directors | ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Dir... |
| 26.04.2023 | National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders | ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on Drug Abuse (NIDA), part of the National Insti... |
| 24.04.2023 | Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning | Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participants |
| 12.04.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS Technology | electroCore Granted Three New U.S. Patents |
| 04.04.2023 | electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute | ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimu... |
| 17.01.2023 | electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update | ROCKAWAY, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the fourth quarter and ... |
| 20.12.2022 | electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep | Truvaga™ handheld non-invasive vagus nerve stimulator offers drug-free 2-minute sessions |
| 07.07.2022 | electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome | Study to be initiated with Mayo Clinic’s Post-COVID Care Clinic subjects |
| 24.05.2022 | electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers | ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available f... |
| 18.01.2022 | electroCore Announces Shareholder Letter and Full-Year 2021 Business Update | Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 |
| 12.01.2022 | gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD) | nVNS reduces symptoms of PTSD by 31% in sham-controlled study |
| 11.01.2022 | electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store | E-Commerce platform allows patients to obtain prescriptions, purchase nVNS devices, and receive training |
| 16.12.2021 | electroCore, Inc. Provides Update on Global Distribution Partners | ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with Melidonia Health Services (Melidonia), ... |
| 15.12.2021 | electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom | ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United Kingdo... |
| 14.12.2021 | electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder | ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing clinical research to assess the potential of gammaC... |
| 13.12.2021 | electroCore Announces New Patent for Stroke and TIA Treatment | ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. ... |
| 04.11.2021 | electroCore Announces Third Quarter 2021 Financial Results | Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 |
| 29.09.2021 | electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 | Study evaluated impact of non-invasive vagus nerve stimulation in hospitalized COVID-19 patients |
| 15.09.2021 | electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices | ECOR’s eighth US patent allows patients to self-treat medical conditions such as migraine headache using non-invasive nerve stimulation via their smartphones |
| 14.09.2021 | electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua | These rare forms of trigeminal autonomic cephalalgias are typically debilitating and difficult to treat |
| 24.08.2021 | electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC | Partnership will expand gammaCore federal market availability |
| 05.08.2021 | electroCore Announces Second Quarter 2021 Financial Results | Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially |
| 27.07.2021 | electroCore Announces Issuance of New Patent for Migraine Treatment Using Smartphones | Newly allowed patent is latest U.S. patent to issue in connection with electroCore’s non-invasive development program for pain |
| 30.06.2021 | electroCore Announces Pricing of $18.0 Million Public Offering of Common Stock | Company intends to use the net proceeds of the offering for sales and marketing, working capital, and general corporate purposes. In addition, it believes that opportunities may exist from time to time to expand its current business through... |
| 24.06.2021 | electroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive Performance Caused by Sleep Deprivation | Peer-reviewed paper available in the journal Communications Biology |
| 23.06.2021 | electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China | Three-year term for exclusive distribution of gammaCore Sapphire™ non-invasive nerve stimulator |
| 16.06.2021 | electroCore to Join Russell Microcap® Index | Effective after the open of trading on June 28, 2021 |
| 02.06.2021 | electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’s Disease Patients | Peer-reviewed paper appears in the journal NPJ Parkinson’s Disease |
| 06.05.2021 | electroCore Announces First Quarter 2021 Financial Results | Record first quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially |
| 26.04.2021 | electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and R... | Economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income |
| 20.04.2021 | electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar | Introduction of nVNS therapy, gammaCore Sapphire, in the Middle East |
| 15.04.2021 | electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache | gammaCore identified as the only therapy that shown to be effective in clinical trials for both acute treatment of episodic cluster headache as well as preventive treatment of cluster headache |
| 13.04.2021 | electroCore Provides Business Update and Select First Quarter 2021 Financial Guidance | ROCKAWAY, NJ, April 13, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited preliminary financial guidance ... |
| 08.04.2021 | electroCore Announces Top Line Results from SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients | nVNS Decreases Certain Biomarkers Associated with the Severity of COVID-19 through Five Days of Treatment |
| 23.03.2021 | electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe | Silvert Medical will serve as exclusive distributor of gammaCore Sapphire™ in Belgium, Luxembourg, the Netherlands, and France |
| 15.03.2021 | Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms | ROCKAWAY, N.J.–(BUSINESS WIRE)–Mar. 15, 2021– Amid the vaccine rollout, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D., Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symp... |
| 11.03.2021 | electroCore Announces Fourth Quarter and Full Year 2020 Financial Results | Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019; Further reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million in the third quarter 2020; Ended 2020 w... |
| 24.02.2021 | Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research | electroCore and the Hospital Clínico Universitario de Valencia have completed patient enrollment in SAVIOR-1 study |
| 11.02.2021 | electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms | Spain-based study has enrolled 110 patients over 18 years of age with respiratory failure secondary to SARS-CoV-2 infection, and is designed to evaluate the incidence of relevant clinical events in patients with active SARS-CoV-2 infection |
| 12.11.2020 | electroCore Announces Third Quarter Financial Results | BASKING RIDGE, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced third quarter 2020 financial results and provided an operational update. |
| 13.08.2020 | electroCore Announces Second Quarter Financial Results | Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations ; generated sequential increase in revenue; further strengthened balance sheet and redu... |
| 28.07.2020 | electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia | Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache |
| 13.11.2019 | electroCore Announces Third Quarter 2019 Financial Results | Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions |
| 30.09.2019 | electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer | 35-year biotechnology and medical technology veteran to lead bio-electric medicine company |
| 25.09.2019 | electroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore™ | Additional information requested by FDA; Premium 2 trial progressing as planned |
| 27.03.2019 | ElectroCore Announces Fourth Quarter and Full Year 2018 Financial Results | Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 |
| 08.03.2019 | ElectroCore Appoints Multiple Industry Veterans to Key Management Positions | Dr. Tony Florino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer |
| 23.10.2018 | Nice Publishes Advice on GammaCore for the Treatment of Cluster Headache in the UK | Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache. |
| 30.11.2017 | Term Sheet — Thursday, November 30 | A WILD WEDNESDAY
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here’s a quick summary of what’s been going on: Bitcoin blew past the $9,000 per coin mark on Sunday. Then, all hell broke loo... |
| 29.11.2017 | electroCore Completes Over $70M Series B Financing | electroCore, a Basking Ridge, NJ-based bioelectronic medicine healthcare company,, completed an over $70m Series B financing.
The round was led by Core Ventures II, with participation from Merck’s Global Health Innovation Fund, Gakasa, Amer... |
